These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16145759)

  • 21. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ; Campen D; Hui R; Spence M; Cheetham C; Levy G; Shoor S; Ray WA
    Lancet; 2005 Feb 5-11; 365(9458):475-81. PubMed ID: 15705456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COX-2 inhibitors still eyed for cancer prevention.
    Thompson CA
    Am J Health Syst Pharm; 2005 May; 62(9):890, 894. PubMed ID: 15851492
    [No Abstract]   [Full Text] [Related]  

  • 23. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
    Meyer CH
    Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
    [No Abstract]   [Full Text] [Related]  

  • 24. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
    [No Abstract]   [Full Text] [Related]  

  • 25. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M; Richard H; Pilote L
    BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Celecoxib and rofecoxib.
    Brinker AD; Bonnel RA; Feight AG; Nourjah P
    J Am Dent Assoc; 2001 Nov; 132(11):1502, 1504. PubMed ID: 11806062
    [No Abstract]   [Full Text] [Related]  

  • 27. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.
    Brownstein JS; Sordo M; Kohane IS; Mandl KD
    PLoS One; 2007 Sep; 2(9):e840. PubMed ID: 17786211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Balancing the risks and benefits of celecoxib.
    Caldwell B; Beasley R; Weatherall M; Metcalfe S
    Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
    [No Abstract]   [Full Text] [Related]  

  • 29. Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
    Nguyen A; Chaiton A
    Can Fam Physician; 2001 Jul; 47():1398-400. PubMed ID: 11494927
    [No Abstract]   [Full Text] [Related]  

  • 30. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH; Sichrovsky T
    Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380
    [No Abstract]   [Full Text] [Related]  

  • 31. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pfizer: Celebrex increases heart attack risk.
    Health News; 2005 Feb; 11(2):2. PubMed ID: 15732142
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cardiovascular events: a class effect by COX-2 inhibitors].
    Araujo LF; Soeiro Ade M; Fernandes Jde L; Serrano Júnior CV
    Arq Bras Cardiol; 2005 Sep; 85(3):222-9. PubMed ID: 16200274
    [No Abstract]   [Full Text] [Related]  

  • 34. Benefit versus risk in the use of non-selective NSAIDs and selective COX-2 inhibitors.
    Aalbers J
    Cardiovasc J Afr; 2012 Jul; 23(6):356. PubMed ID: 23091830
    [No Abstract]   [Full Text] [Related]  

  • 35. COX-2 inhibitors: no pain, no heart gain?
    Harv Heart Lett; 2001 Dec; 12(4):2-4. PubMed ID: 11751079
    [No Abstract]   [Full Text] [Related]  

  • 36. [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].
    Zeidler H
    MMW Fortschr Med; 2001 Sep; 143(35-36):14. PubMed ID: 11584521
    [No Abstract]   [Full Text] [Related]  

  • 37. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
    Weaver A; Alderman M; Sperling R
    Am J Cardiol; 2003 May; 91(10):1291-2. PubMed ID: 12745131
    [No Abstract]   [Full Text] [Related]  

  • 38. COX-2 inhibitors and risk of heart failure.
    Kammerl MC; Debler J; Riegger GA; Krämer BK
    Lancet; 2004 Oct 23-29; 364(9444):1486-7; author reply 1487. PubMed ID: 15500886
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiovascular risk associated with celecoxib.
    Brophy JM
    N Engl J Med; 2005 Jun; 352(25):2648-50; author reply 2648-50. PubMed ID: 15972876
    [No Abstract]   [Full Text] [Related]  

  • 40. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.